



FOR IMMEDIATE RELEASE

August 14, 2020

Contact: Brian Huber

Phone: (214) 563-4472

Email: bhuber@aptt3x.com

Indiana/Texas-Based Health Company Announces Successful Test of a Formulation that Blocks COVID (Coronavirus) from Nasal Passages

As World Waits for a Vaccine, Efforts are Being Made to Find Alternative Ways to Prevent COVID

(Indianapolis, Indiana and Rockwall, Texas - August 14, 2020) Advanced Penetration Technology, LLC, (APT) a Texas-and Indiana-based company (www.aptdeliverysystem.com) that specializes in innovative solutions for patient care utilizing non-prescription (OTC) products, today released results of an independent laboratory evaluation of a topical medical formulation that mitigates the Coronavirus from entering the body through the nasal passages, thereby significantly reducing the likelihood of people becoming infected with the virus.

“We believe this will be a breakthrough that will reduce the likelihood of becoming infected with Coronavirus through the nose, which is where most cases are contracted,” said Dr. Brian J. Huber, the CEO and Founder of APT, LLC. “This is a big deal. It is the type of protection a lot of people have been hoping for and could

be a first line of defense against the COVID virus. It is a powerful and effective layer of prevention.”

Until a vaccine is developed, some medical researchers have turned their attention on new ways to mitigate or prevent the risk of people contracting COVID-19. Since no one knows how long it will be until there is an effective vaccine, APT set out to determine if an existing product, already in use as a highly effective anti-fungal, anti-bacterial topical therapy might be effective against the virus.

Just as soap has been shown to be effective in reducing the likelihood of the virus entering the body after contact with the hands, APT believed its formulation might reduce the likelihood of the virus entering the body through the nose.

A London-based research laboratory, Virology Research Services Ltd., evaluated the anti-viral impact of the product, named APT™ T3X, against the [Corona Virus \(NL63\)](#) and [Influenza A virus](#) and concluded that it is a highly effective formulation against the Coronavirus. The research concludes that APT™ T3X effectively neutralizes viral infectivity within seconds. The anti-viral efficacy supports the topical intranasal use of APT™ T3X to decrease the viral load of exposure.

“Under the conditions tested, APT T3X displays a 99.9% virucidal activity against human coronavirus NL63,” the report concluded.

The testing was performed over two months, in May and June, 2020. All definitive anti-viral assays were performed in triplicate.

APT™T3X is a topical liquid formulation applied inside the nasal passages by a cotton tip applicator (like a Q-tip®) with 3-4 drops on the tip. People simply need to “paint” the nasal channels and inside of their nostrils with the cotton tip applicator.

By coating the nasal passages, a barrier is formed that will reduce the viral load of

exposure. The efficacy of APT™T3X is due to APT's proprietary formulation combined with Tetracycline hydrochloride as the active pharmaceutical ingredient. The product is registered with the Federal Drug Administration as an over-the-counter ointment, used in an off-label manner to decrease the viral load of exposure.

The product was initially developed eight years ago for resistant-bacterial infections, but its formulation additionally provides powerful anti-fungal and anti-viral therapies. It has no documented side effects, however patients diagnosed with Lyme Disease should be aware of a potential "Herx" reaction shortly after use.

"As this virus took off last Spring, we thought the APT™T3X product had a chance of preventing or reducing the ability of the virus to enter the human body through the nose," Huber said. "We felt it was our call-to-duty to try. That's why we sent APT™ T3X to an independent virology lab for proper antiviral evaluation and tests. We're highly encouraged by the laboratory results and conclusions. The APT™ T3X is also a highly effective antiviral formulation. Until there is a vaccine, the best thing we can do is prevent the virus from entering someone's body through the nose, which is what our product does."

Even with the use of APT™T3X, the virus may still enter a body through the mouth and the eyes. However, a recent [study](#) by the Massachusetts Institute of Technology (MIT) concluded that people contract COVID-19 and other viruses primarily through the nose. In addition to following CDC guidelines, the APT™T3X provides ANOTHER layer of needed preventative protection.

The product is available at the APT website, www.aptt3x.com. Plans are underway to scale for mass production.

About Advanced Penetration Technology, LLC:

Advanced Penetration Technology, LLC, is an Indiana- and Texas-based company that creates new solutions for areas of patient care utilizing over-the-counter product platforms. Its products have been used to treat wounds, burns, acne and other conditions. Founded in 2016, APT strives to provide access to highly effective care at the primary and home levels on a global scale. The Advanced Penetration Technology has been shown in preliminary laboratory testing to provide significantly improved penetration of certain medications at the target site, allowing for improved effectiveness in certain topically applied products and creating a more optimal environment for a more rapid healing process.

About Brian J. Huber D.V.M., A.B.V.P:

Dr. Brian J. Huber is the CEO and Founder of Advanced Penetration Technology (APT), LLC. A graduate of Kansas State University where he received his doctorate in veterinary medicine, Dr. Huber has over 30 years of experience working in the human medical and veterinary arenas. Among his current duties with APT, Dr. Huber also serves as Chief Medical Officer at BioPharma Products, LLC, and the President of Aliquis Telepresence: Division of Hodei Technology. Dr. Huber's breadth of experiences across many healthcare continuums, has provided insight and access to technology and business opportunities in both human and veterinary businesses.

